Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07189819

Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait

This study will compare the performance of a novel data-driven model-predictive controller (MPC) based functional electrical stimulation (FES) system versus a conventional FES system for footdrop correction during treadmill and overground walking tasks in people post-stroke.

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Emory Rehabilitation Hospital

Atlanta, Georgia, 30322, United States

Location status: Recruiting

About this study

Functional electrical stimulation (FES) is a common rehabilitation tool that incorporates electrical stimulation timed with a functional task to augment paretic muscle function in people with neuro-pathologies such as stroke and spinal cord injury. The rigor of previous research has established the safety, as well as both neuro-prosthetic and therapeutic effects of FES systems for standing, walking, and grasping. Stroke is the leading cause of disability, and footdrop is a highly prevalent post-stroke gait deficit, leading to insufficient ankle dorsiflexion during the swing phase of gait, and contributing to reduced mobility. FES systems that correct footdrop to improve gait function and reduce fall risk are gaining popularity, with commercial systems such as enhancing translation potential. Despite their promising functional value, accessibility, and positive neuroplasticity effects, current FES systems have some fundamental limitations, which limit their clinical prescription.

The goal of this project is to overcome two major limitations and technical gaps in FES: rapid onset of muscle fatigue during FES and lack of sophisticated closed-loop control of FES intensity. Most existing FES systems do not automatically modulate stimulation intensity in response to muscle fatigue, and may overstimulate the muscles if fixed (open-loop) stimulation or a pure feedback-based stimulation strategy is used to control FES intensity. To address this limitation, the researchers aim to develop and clinically test FES for improving stroke gait using data-driven FES control systems.

Footdrop is a highly prevalent post-stroke gait deficit, leading to insufficient ankle dorsiflexion during the swing phase of gait, and reducing functional mobility. FES, which is an external application of stimulation to generate muscle contractions during a functional motor task, can achieve muscle force demands during standing and walking, and help persons with stroke and spinal cord injury recover mobility. FES for the correction of footdrop is one of the most popular gait applications of FES, which has been shown to improve mobility and reduce falls.

Although FES has positive effects on walking function, elicits active muscle contractions, and enhances corticomotor excitability, FES is not used as commonly as passive orthotics. Most current FES systems incorporate motion sensors to control the timing of FES during the gait cycle (paretic leg swing phase). However, none of these systems provide automatic closed-loop control of FES intensity, so that optimal stimulation can be delivered for each step, preventing over-stimulation, reducing fatigue, and maintaining optimal muscle performance for a greater number of steps. Additionally, rapid onset of muscle fatigue during FES is caused by synchronous, non-selective, repeated recruitment of largely fatigable muscle fibers.

The researchers will implement an innovative model-predictive controller (MPC) combined with real-time ultrasound-based feedback to deliver optimal FES intensities and minimize fatigue.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • >6 months since stroke
  • cortical or subcortical stroke
  • able to walk 10-meters with or without an assistive device
  • sufficient cardiovascular health and ankle stability to walk on treadmill without ankle orthosis
  • passive ankle range of motion to benefit from dorsiflexor FES assistance
  • resting heart rate 40-100 bpm

Exclusion criteria

  • cerebellar signs
  • score >1 on question 1b (does not know the current month and age) and >0 on question 1c (can not blink eyes and squeeze hands) on NIH Stroke Scale
  • inability to communicate with investigators
  • neglect/hemianopia
  • unexplained dizziness in past 6 months
  • sensory loss in paretic leg
  • musculoskeletal or medical conditions limiting walking
  • neurologic diagnoses other than stroke

Treatment and study plan

Model-Predictive Controller (MPC) Functional Electrical Stimulation (FES)

Device

The model-predictive controller (MPC) determines the timing and intensity of electrical stimulation delivered for FES. MPC combined with real-time ultrasound-based feedback delivers optimal FES intensities and minimizes fatigue. FES is delivered to the ankle dorsiflexor muscles using a commercially available FDA-approved electrical stimulator.

Conventional Functional Electrical Stimulation (FES)

Device

For functional electrical stimulation, surface electrodes are placed on the paretic leg on skin overlying the tibialis anterior (TA) muscle, with intensity pre-set to elicit dorsiflexion to neutral against gravity. FES will be delivered to the ankle dorsiflexor muscles using a commercially available FDA-approved electrical stimulator.

Primary outcomes

  1. Number of Adverse Events

    Time frame: Day 1

    Safety is assessed as the number of adverse events experienced by study participants.

  2. Count of Risks

    Time frame: Day 1

    Safety is assessed as the count of risks, including falling, discomfort, pain, skin problems, fatigue, and soreness.

  3. Participant Perception of Comfort

    Time frame: Day 1

    Participant perception of comfort is measured on an 10-point Likert scale ranging from 1 to 10, where 10 is the most comfortable.

  4. Participant Perception of Acceptability

    Time frame: Day 1

    Participant perception of acceptability is measured on an 10-point Likert scale ranging from 1 to 10, where 10 is the most acceptable.

  5. Percent of Gait Cycles with Footdrop Correction

    Time frame: Day 1

    Feasibility of the FES control system is assessed as the percentage of gait cycles with footdrop correction. The FES control system is considered effective if greater than 80% of gait cycles have footdrop correction.

  6. Number of Participants Completing Gait Bouts

    Time frame: Day 1

    Feasibility of the FES control system is assessed as the number of participants who are able to complete gait bouts with the MPC FES system. The FES control system is considered effective if greater than 80% of participants are able to complete gait bouts.

Secondary outcomes

  1. Peak Ankle Dorsiflexion Angle During Swing

    Time frame: Day 1

    Gait biomechanics performance is assessed as the peak ankle dorsiflexion angle during swing. The normal range for peak ankle dorsiflexion is 0 to 5 degrees.

  2. Overground Walking Distance

    Time frame: Day 1

    Gait performance is assessed as overground walking distance traveled, in meters, during a 6-minute walk test.

  3. FES Intensity

    Time frame: Day 1

    FES system performance is assessed as FES intensity. FES intensity is measured during a treadmill walking bout. Intensity is measured by milliamps (mA) or millivolts (mV).

Study contacts

Contact information is provided by the study sponsor or research team.

Trisha Kesar, PT, PhD

CONTACT

[email protected]

(404) 712-5803

Sponsors and collaborators

Lead sponsor

Emory University

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Sep 24, 2025
Registry last updated
Jul 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.